{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:06:33Z","timestamp":1793325993518,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003033","name":"Ministerio de Ciencia, Tecnolog\u00eda e Innovaci\u00f3n Productiva","doi-asserted-by":"publisher","award":["PICT-2014-3216"],"award-info":[{"award-number":["PICT-2014-3216"]}],"id":[{"id":"10.13039\/501100003033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003033","name":"Ministerio de Ciencia, Tecnolog\u00eda e Innovaci\u00f3n Productiva","doi-asserted-by":"publisher","award":["PICT V 2014-3687"],"award-info":[{"award-number":["PICT V 2014-3687"]}],"id":[{"id":"10.13039\/501100003033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003033","name":"Ministerio de Ciencia, Tecnolog\u00eda e Innovaci\u00f3n Productiva","doi-asserted-by":"publisher","award":["PICT-2016-1139"],"award-info":[{"award-number":["PICT-2016-1139"]}],"id":[{"id":"10.13039\/501100003033","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sales, Bunge & Born and Lounsbery Foundations. Donations from the Ferioli, Ostry and Caraballo families."},{"DOI":"10.13039\/501100005363","name":"Universidad de Buenos Aires","doi-asserted-by":"publisher","award":["20020150100005BA"],"award-info":[{"award-number":["20020150100005BA"]}],"id":[{"id":"10.13039\/501100005363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","award":["PIP-11220150100647"],"award-info":[{"award-number":["PIP-11220150100647"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Galectin-1 (GAL1), a \u03b2-galactoside-binding protein abundantly expressed in the tumor microenvironment, has emerged as a key mechanism of chemoresistance developed by different tumors. Although increased expression of GAL1 is a hallmark of hepatocellular carcinoma (HCC) progression, aggressiveness and metastasis, limited information is available on the role of this endogenous lectin in HCC resistance to chemotherapy. Moreover, the precise mechanisms underlying this effect are uncertain. HCC has evolved different mechanisms of resistance to chemotherapy including those involving the P-glycoprotein (P-gp), an ATP-dependent drug efflux pump, which controls intracellular drug concentration. Here, we investigated the molecular mechanism underlying GAL1-mediated chemoresistance in HCC cells, particularly the involvement of P-gp in this effect. Our results show that GAL1 protected HepG2 cells from doxorubicin (DOX)- and sorafenib-induced cell death in vitro. Accordingly, GAL1-overexpressing HepG2 cells generated DOX-resistant tumors in vivo. High expression of GAL1 in HepG2 cells reduced intracellular accumulation of DOX likely by increasing P-gp protein expression rather than altering its membrane localization. GAL1-mediated increase of P-gp expression involved activation of the phosphatidylinositol-3 kinase (PI3K) signaling pathway. Moreover, \u2018loss-of-function\u2019 experiments revealed that P-gp mediates GAL1-driven resistance to DOX, but not to sorafenib, in HepG2 cells. Conversely, in PLC\/PRF\/5 cells, P-gp protein expression was undetectable and GAL1 did not control resistance to DOX or sorafenib, supporting the critical role of P-gp in mediating GAL1 effects. Collectively, our findings suggest that GAL1 confers chemoresistance in HCC through mechanisms involving modulation of P-gp, thus emphasizing the role of this lectin as a potential therapeutic target in HCC.<\/jats:p>","DOI":"10.1038\/s41419-022-04520-6","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T07:03:43Z","timestamp":1643007823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Galectin-1 confers resistance to doxorubicin in hepatocellular carcinoma cells through modulation of P-glycoprotein expression"],"prefix":"10.1038","volume":"13","author":[{"given":"Pablo","family":"Carabias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda V.","family":"Espelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda L.","family":"Bacigalupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Sarrias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayel\u00e9n","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00e1s A.","family":"Saffioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda T.","family":"Elola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Wolfenstein-Todel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0947-8735","authenticated-orcid":false,"given":"Gabriel A.","family":"Rabinovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4919-9976","authenticated-orcid":false,"given":"Mar\u00eda F.","family":"Troncoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"key":"4520_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin."},{"key":"4520_CR2","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","volume":"5","author":"C Fitzmaurice","year":"2019","unstructured":"Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-Adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5:1749\u201368.","journal-title":"JAMA Oncol."},{"key":"4520_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","volume":"156","author":"L Kulik","year":"2019","unstructured":"Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156:477\u201391.","journal-title":"Gastroenterology"},{"key":"4520_CR4","first-page":"1301","volume":"391","author":"A Forner","year":"2006","unstructured":"Forner A, Hessheimer AJ, Isabel Real M, Bruix J. Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol. 2006;391:1301\u201314.","journal-title":"Crit Rev Oncol Hematol."},{"key":"4520_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","volume":"15","author":"JM Llovet","year":"2018","unstructured":"Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599\u2013616.","journal-title":"Nat Rev Clin Oncol."},{"key":"4520_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ctrv.2018.05.006","volume":"68","author":"JL Raoul","year":"2018","unstructured":"Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat Rev. 2018;68:16\u201324.","journal-title":"Cancer Treat Rev."},{"key":"4520_CR7","doi-asserted-by":"publisher","first-page":"59950","DOI":"10.18632\/oncotarget.19048","volume":"8","author":"HC Zheng","year":"2017","unstructured":"Zheng HC. The molecular mechanisms of chemoresistance in cancers. Oncotarget. 2017;8:59950\u201364.","journal-title":"Oncotarget"},{"key":"4520_CR8","doi-asserted-by":"publisher","first-page":"113959","DOI":"10.1016\/j.bcp.2020.113959","volume":"177","author":"H Muley","year":"2020","unstructured":"Muley H, Fad\u00f3 R, Rodr\u00edguez-Rodr\u00edguez R, Casals N. Drug uptake-based chemoresistance in breast cancer treatment. Biochem Pharmacol. 2020;177:113959.","journal-title":"Biochem Pharmacol."},{"key":"4520_CR9","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Schaeybroeck SVan, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714\u201326.","journal-title":"Nat Rev Cancer"},{"key":"4520_CR10","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jhep.2011.07.031","volume":"56","author":"U Asghar","year":"2012","unstructured":"Asghar U, Meyer T. Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol. 2012;56:686\u201395.","journal-title":"J Hepatol."},{"key":"4520_CR11","first-page":"6995","volume":"8","author":"B Gao","year":"2015","unstructured":"Gao B, Yang FM, Yu ZT, Li R, Xie F, Chen J, et al. Relationship between the expression of MDR1 in hepatocellular cancer and its biological behaviors. Int J Clin Exp Pathol. 2015;8:6995\u20137001.","journal-title":"Int J Clin Exp Pathol."},{"key":"4520_CR12","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1248\/bpb.30.1400","volume":"30","author":"Y Takeba","year":"2007","unstructured":"Takeba Y, Sekine S, Kumai T, Matsumoto N, Nakaya S, Tsuzuki Y, et al. Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells. Biol Pharm Bull. 2007;30:1400\u20136.","journal-title":"Biol Pharm Bull"},{"key":"4520_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cddis.2011.44","volume":"2","author":"C Muglia","year":"2011","unstructured":"Muglia C, Mercer N, Toscano MA, Schattner M, Pozner R, Cerliani JP, et al. The glycan-binding protein galectin-1 controls survival of epithelial cells along the crypt-villus axis of small intestine. Cell Death Dis. 2011;2:1\u201312.","journal-title":"Cell Death Dis."},{"key":"4520_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.506","volume":"8","author":"T Clemente","year":"2017","unstructured":"Clemente T, Vieira NJ, Cerliani JP, Adrain C, Luthi A, Dominguez MR, et al. Proteomic and functional analysis identifies galectin-1 as a novel regulatory component of the cytotoxic granule machinery. Cell Death Dis. 2017;8:e3176.","journal-title":"Cell Death Dis."},{"key":"4520_CR15","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1007\/s00018-007-7044-8","volume":"64","author":"MT Elola","year":"2007","unstructured":"Elola MT, Wolfenstein-Todel C, Troncoso MF, Vasta GR, Rabinovich GA. Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci. 2007;64:1679\u2013700.","journal-title":"Cell Mol Life Sci."},{"key":"4520_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cellimm.2018.03.008","volume":"333","author":"MT Elola","year":"2018","unstructured":"Elola MT, Ferragut F, M\u00e9ndez-Huergo SP, Croci DO, Bracalente C, Rabinovich GA. Galectins: multitask signaling molecules linking fibroblast, endothelial and immune cell programs in the tumor microenvironment. Cell Immunol. 2018;333:34\u201345.","journal-title":"Cell Immunol."},{"key":"4520_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ctrv.2013.07.007","volume":"40","author":"L Astorgues-Xerri","year":"2014","unstructured":"Astorgues-Xerri L, Riveiro ME, Tijeras-raballand A, Serova M, Neuzillet C, Albert S, et al. Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev. 2014;40:307\u201319.","journal-title":"Cancer Treat Rev."},{"key":"4520_CR18","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1016-8478(23)15119-3","volume":"14","author":"EJ Chung","year":"2002","unstructured":"Chung EJ, Sung YK, Farooq M, Kim Y, Im S, Tak WY, et al. Gene expression profile analysis in human hepatocellular carcinoma by cDNA microarray. Mol Cells. 2002;14:382\u20137.","journal-title":"Mol Cells"},{"key":"4520_CR19","first-page":"1575","volume":"23","author":"N Kondoh","year":"2003","unstructured":"Kondoh N, Hada A, Ryo A, Shuda M, Arai M, Matsubara O, et al. Activation of Galectin-1 gene in human hepatocellular carcinoma involves methylation-sensitive complex formations at the transcriptional upstream and downstream elements. Int J Oncol. 2003;23:1575\u201383.","journal-title":"Int J Oncol."},{"key":"4520_CR20","doi-asserted-by":"publisher","first-page":"8831","DOI":"10.3748\/wjg.v19.i47.8831","volume":"19","author":"ML Bacigalupo","year":"2013","unstructured":"Bacigalupo ML, Manzi M, Rabinovich GA, Troncoso MF. Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma. World J Gastroenterol. 2013;19:8831\u201349.","journal-title":"World J Gastroenterol."},{"key":"4520_CR21","doi-asserted-by":"publisher","first-page":"5266","DOI":"10.3748\/wjg.v23.i29.5266","volume":"23","author":"ML Bacigalupo","year":"2017","unstructured":"Bacigalupo ML, Carabias P, Troncoso MF. Contribution of galectin-1, a glycan-binding protein, to gastrointestinal tumor progression. World J Gastroenterol. 2017;23:5266\u201381.","journal-title":"World J Gastroenterol."},{"key":"4520_CR22","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1111\/j.1440-1746.2012.07130.x","volume":"27","author":"H Wu","year":"2012","unstructured":"Wu H, Chen P, Liao R, Li Y, Yi Y, Wang J, et al. Overexpression of galectin-1 is associated with poor prognosis in human hepatocellular carcinoma following resection. J Gastroenterol Hepatol. 2012;27:1312\u20139.","journal-title":"J Gastroenterol Hepatol."},{"key":"4520_CR23","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1002\/hep.24294","volume":"53","author":"MV Espelt","year":"2011","unstructured":"Espelt MV, Croci DO, Bacigalupo ML, Carabias P, Manzi M, Elola MT, et al. Novel roles of galectin-1 in hepatocellular carcinoma cell adhesion, polarization, and in vivo tumor growth. Hepatology. 2011;53:2097\u2013106.","journal-title":"Hepatology"},{"key":"4520_CR24","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/hep.26335","volume":"58","author":"T Potikha","year":"2013","unstructured":"Potikha T, Stoyanov E, Pappo O, Frolov A, Mizrahi L, Olam D, et al. Interstrain differences in chronic hepatitis and tumor development in a murine model of inflammation-mediated hepatocarcinogenesis. Hepatology. 2013;58:192\u2013204.","journal-title":"Hepatology"},{"key":"4520_CR25","doi-asserted-by":"publisher","first-page":"7995","DOI":"10.1096\/fj.201900017R","volume":"33","author":"T Potikha","year":"2019","unstructured":"Potikha T, Pappo O, Mizrahi L, Olam D, Maller SM, Rabinovich GA, et al. Lack of galectin-1 exacerbates chronic hepatitis, liver fibrosis, and carcinogenesis in murine hepatocellular carcinoma model. FASEB J. 2019;33:7995\u20138007.","journal-title":"FASEB J."},{"key":"4520_CR26","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1530\/EC-19-0292","volume":"8","author":"ML Bacigalupo","year":"2019","unstructured":"Bacigalupo ML, Piazza VG, Cicconi NS, Carabias P, Bartke A, Fang Y, et al. Growth hormone upregulates the pro-tumrigenic galectin 1 in mouse liver. Endocr Connect 2019;8:1108\u201317.","journal-title":"Endocr Connect"},{"key":"4520_CR27","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/jcp.24865","volume":"230","author":"ML Bacigalupo","year":"2015","unstructured":"Bacigalupo ML, Manzi M, Espelt MV, Gentilini LD, Compagno D, Laderach DJ, et al. Galectin-1 triggers epithelial-mesenchymal transition in human hepatocellular carcinoma cells. J Cell Physiol. 2015;230:1298\u2013309.","journal-title":"J Cell Physiol."},{"key":"4520_CR28","first-page":"38","volume":"3","author":"C Hill","year":"2020","unstructured":"Hill C, Wang Y. The importance of epithelial-mesenchymal transition and autophagy in cancer drug resistance. Cancer Drug Resist. 2020;3:38\u201347.","journal-title":"Cancer Drug Resist."},{"key":"4520_CR29","doi-asserted-by":"publisher","first-page":"100773","DOI":"10.1016\/j.tranon.2020.100773","volume":"13","author":"D Ribatti","year":"2020","unstructured":"Ribatti D, Tamma R, Annese T. Epithelial-mesenchymal transition in cancer: a historical overview. Transl Oncol. 2020;13:100773.","journal-title":"Transl Oncol."},{"key":"4520_CR30","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1002\/jcp.25244","volume":"231","author":"M Manzi","year":"2016","unstructured":"Manzi M, Bacigalupo ML, Carabias P, Elola MT, Wolfenstein-Todel C, Rabinovich GA, et al. Galectin-1 controls the proliferation and migration of liver sinusoidal endothelial cells and their interaction with hepatocarcinoma cells. J Cell Physiol. 2016;231:1522\u201333.","journal-title":"J Cell Physiol."},{"key":"4520_CR31","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1074\/mcp.M114.046417","volume":"14","author":"CC Yeh","year":"2015","unstructured":"Yeh CC, Hsu CH, Shao YY, Ho WC, Tsai M. Integrated SILAC and iTRAQ quantitative proteomic analysis identifies galectin-1 as a potential biomarker for predicting sorafenib resistance in liver cancer. Mol Cell Proteom. 2015;14:1527\u201345.","journal-title":"Mol Cell Proteom"},{"key":"4520_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.324","volume":"7","author":"PF Zhang","year":"2016","unstructured":"Zhang PF, Li KS, Shen YH, Gao PT, Dong ZR, Cai JB, et al. Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK\/PI3K\/AKT signaling. Cell Death Dis. 2016;7:e2201.","journal-title":"Cell Death Dis."},{"key":"4520_CR33","doi-asserted-by":"publisher","first-page":"e0148408","DOI":"10.1371\/journal.pone.0148408","volume":"11","author":"YC Su","year":"2016","unstructured":"Su YC, Davuluri GVN, Chen CH, Shiau DC, Chen CC, Chen CL, et al. Galectin-1-induced autophagy facilitates cisplatin resistance of hepatocellular carcinoma. PLoS ONE. 2016;11:e0148408.","journal-title":"PLoS ONE"},{"key":"4520_CR34","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1084\/jem.190.3.385","volume":"190","author":"GA Rabinovich","year":"1999","unstructured":"Rabinovich GA, Daly G, Dreja H, Tailor H, Riera CM, Hirabayashi J, et al. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J Exp Med. 1999;190:385\u201398.","journal-title":"J Exp Med."},{"key":"4520_CR35","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.bbamcr.2019.03.010","volume":"1866","author":"F Ferragut","year":"2019","unstructured":"Ferragut F, Cagnoni AJ, Colombo LL, S\u00e1nchez Terrero C, Wolfenstein-Todel C, Troncoso MF, et al. Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM\/CD166), synergistically delays in vivo breast cancer growth. Biochim Biophys Acta \u2013 Mol Cell Res. 2019;1866:1338\u201352.","journal-title":"Biochim Biophys Acta \u2013 Mol Cell Res."},{"key":"4520_CR36","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.18632\/oncotarget.1922","volume":"5","author":"G Sequeira","year":"2014","unstructured":"Sequeira G, Vanzulli SI, Rojas P, Lamb C, Colombo L, May M, et al. The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer. Oncotarget. 2014;5:3246\u201360.","journal-title":"Oncotarget"},{"key":"4520_CR37","doi-asserted-by":"publisher","first-page":"G93","DOI":"10.1152\/ajpgi.90410.2008","volume":"296","author":"MC Larocca","year":"2009","unstructured":"Larocca MC, Soria LR, Espelt MV, Lehmann GL, Marinelli RA. Knockdown of hepatocyte aquaporin-8 by RNA interference induces defective bile canalicular water transport. Am J Physiol \u2013 Gastrointest Liver Physiol. 2009;296:G93\u2013100.","journal-title":"Am J Physiol \u2013 Gastrointest Liver Physiol."},{"key":"4520_CR38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/0014-5793(94)01186-9","volume":"355","author":"V Lecureur","year":"1994","unstructured":"Lecureur V, Fardel O, Guillouzo A. The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett. 1994;355:187\u201391.","journal-title":"FEBS Lett."},{"key":"4520_CR39","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1177\/147323001204000204","volume":"40","author":"H Sui","year":"2012","unstructured":"Sui H, Fan ZZ, Li Q. Signal transuction pathways and transcriptional mechanisms of ABCB1\/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res. 2012;40:426\u201335.","journal-title":"J Int Med Res."},{"key":"4520_CR40","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/ijc.1498","volume":"94","author":"AT Nies","year":"2001","unstructured":"Nies AT, K\u00f6nig J, Pfannschmidt M, Klar E, Hofmann WJ, Keppler D. Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer. 2001;94:492\u20139.","journal-title":"Int J Cancer"},{"key":"4520_CR41","first-page":"965","volume":"23","author":"PV Korita","year":"2010","unstructured":"Korita PV, Wakai T, Shirai Y, Matsuda Y, Sakata J, Takamura M, et al. Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol Rep. 2010;23:965\u201372.","journal-title":"Oncol Rep."},{"key":"4520_CR42","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.taap.2008.01.009","volume":"229","author":"M Le Mercier","year":"2008","unstructured":"Le Mercier M, Lefranc F, Mijatovic T, Debeir O, Haibe-Kains B, Bontempi G, et al. Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol. 2008;229:172\u201383.","journal-title":"Toxicol Appl Pharmacol."},{"key":"4520_CR43","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1158\/1078-0432.CCR-11-3348","volume":"18","author":"LY Chung","year":"2012","unstructured":"Chung LY, Tang SJ, Sun GH, Chou TY, Yeh TS, Yu SL, et al. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2. Clin Cancer Res. 2012;18:4037\u201347.","journal-title":"Clin Cancer Res."},{"key":"4520_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.526","volume":"5","author":"P Zhang","year":"2014","unstructured":"Zhang P, Zhang P, Shi B, Zhou M, Jiang H, Zhang H, et al. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer. Cell Death Dis. 2014;5:e991.","journal-title":"Cell Death Dis."},{"key":"4520_CR45","doi-asserted-by":"publisher","first-page":"8204","DOI":"10.18632\/aging.102313","volume":"11","author":"PF Zhang","year":"2019","unstructured":"Zhang PF, Wu J, Luo JH, Li KS, Wang F, Huang W, et al. SNHG22 overexpression indicates poor prognosis and induces chemotherapy resistance via the miR-2467\/Gal-1 signaling pathway in epithelial ovarian carcinoma. Aging. 2019;11:8204\u201316.","journal-title":"Aging"},{"key":"4520_CR46","doi-asserted-by":"publisher","first-page":"26709","DOI":"10.18632\/oncotarget.8489","volume":"7","author":"W Luo","year":"2016","unstructured":"Luo W, Song L, Chen XL, Zeng XF, Wu JZ, Zhu CR, et al. Identification of galectin-1 as a novel mediator for chemoresistance in chronic myeloid leukemia cells. Oncotarget. 2016;7:26709\u201323.","journal-title":"Oncotarget"},{"key":"4520_CR47","doi-asserted-by":"publisher","first-page":"35804","DOI":"10.18632\/oncotarget.16208","volume":"8","author":"K Nam","year":"2017","unstructured":"Nam K, Son S, Oh S, Jeon D, Kim H, Noh D-Y, et al. Binding of galectin-1 to integrin \u03b21 potentiates drug resistance by promoting survivin expression in breast cancer cells. Oncotarget. 2017;8:35804\u201323.","journal-title":"Oncotarget"},{"key":"4520_CR48","doi-asserted-by":"crossref","unstructured":"Zhu H, Chen A, Li S, Tao X, Sheng B, Chetry M, et al. Predictive role of galectin-1 and integrin \u03b15\u03b21 in cisplatin-based neoadjuvant chemotherapy of bulky squamous cervical cancer. Biosci Rep. 2017;37:BSR20170958.","DOI":"10.1042\/BSR20170958"},{"key":"4520_CR49","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cbi.2018.10.014","volume":"297","author":"J Gao","year":"2019","unstructured":"Gao J, Wang W. Knockdown of galectin-1 facilitated cisplatin sensitivity by inhibiting autophagy in neuroblastoma cells. Chem Biol Interact. 2019;297:50\u20136.","journal-title":"Chem Biol Interact."},{"key":"4520_CR50","doi-asserted-by":"publisher","first-page":"6086","DOI":"10.1158\/1078-0432.CCR-18-3870","volume":"26","author":"P Navarro","year":"2020","unstructured":"Navarro P, Mart\u00ednez-Bosch N, Blidner AG, Rabinovich GA. Impact of galectins in resistance to anticancer therapies. Clin Cancer Res. 2020;26:6086\u2013101.","journal-title":"Clin Cancer Res."},{"key":"4520_CR51","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1872-034X.2012.01067.x","volume":"43","author":"CG Ye","year":"2013","unstructured":"Ye CG, Yeung JH, Huang GL, Cui P, Wang J, Zou Y, et al. Increased glutathione and mitogen-activated protein kinase phosphorylation are involved in the induction of doxorubicin resistance in hepatocellular carcinoma cells. Hepatol Res. 2013;43:289\u201399.","journal-title":"Hepatol Res."},{"key":"4520_CR52","doi-asserted-by":"publisher","unstructured":"Estevinho MM, Fernandes C, Silva JC, Gomes AC, Afecto E, Correia J, et al. Role of ATP-binding cassette transporters in sorafenib therapy for hepatocellular carcinoma: an overview. Curr Drug Targets. 2021. https:\/\/doi.org\/10.2174\/1389450122666210412125018.","DOI":"10.2174\/1389450122666210412125018"},{"key":"4520_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/srep24165","volume":"6","author":"O Bla\u017eevit\u0161","year":"2016","unstructured":"Bla\u017eevit\u0161 O, Mideksa YG, \u0160olman M, Ligabue A, Ariotti N, Nakhaeizadeh H, et al. Galectin-1 dimers can scaffold Raf-effectors to increase H-ras nanoclustering. Sci Rep. 2016;6:24165.","journal-title":"Sci Rep."},{"key":"4520_CR54","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1517\/14728222.2013.764990","volume":"17","author":"A Takashima","year":"2013","unstructured":"Takashima A, Faller DV. Targeting the RAS oncogene. Expert Opin Ther Targets. 2013;17:507\u201331.","journal-title":"Expert Opin Ther Targets."},{"key":"4520_CR55","doi-asserted-by":"publisher","first-page":"4052","DOI":"10.3390\/ijms19124052","volume":"19","author":"H Sch\u00f6neborn","year":"2018","unstructured":"Sch\u00f6neborn H, Raudzus F, Coppey M, Neumann S, Heumann R. Perspectives of RAS and RHEB GTPase signaling pathways in regenerating brain neurons. Int J Mol Sci. 2018;19:4052.","journal-title":"Int J Mol Sci."},{"key":"4520_CR56","first-page":"1303","volume":"34","author":"S Seo","year":"2009","unstructured":"Seo S, Hatano E, Higashi T, Nakajima A, Nakamoto Y, Tada M, et al. P-glycoprotein expression affects 18F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro. Int J Oncol. 2009;34:1303\u201312.","journal-title":"Int J Oncol."},{"key":"4520_CR57","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejphar.2017.03.045","volume":"803","author":"HB Xu","year":"2017","unstructured":"Xu HB, Fu J, Huang F, Yu J. Guggulsterone sensitized drug-resistant human hepatocarcinoma cells to doxorubicin through a Cox-2\/P-gp dependent pathway. Eur J Pharmacol. 2017;803:57\u201364.","journal-title":"Eur J Pharmacol."},{"key":"4520_CR58","doi-asserted-by":"publisher","first-page":"9721","DOI":"10.2147\/OTT.S262089","volume":"13","author":"Y Li","year":"2020","unstructured":"Li Y, Chen G, Han Z, Cheng H, Qiao L, Li Y. IL-6\/STAT3 signaling contributes to sorafenib resistance in hepatocellular carcinoma through targeting cancer stem cells. Onco Targets Ther. 2020;13:9721\u201330.","journal-title":"Onco Targets Ther."},{"key":"4520_CR59","first-page":"907","volume":"83","author":"EN Yakusheva","year":"2018","unstructured":"Yakusheva EN, Titov DS. Structure and function of multidrug resistance protein 1. Biochemistry 2018;83:907\u201329.","journal-title":"Biochemistry"},{"key":"4520_CR60","doi-asserted-by":"publisher","first-page":"344","DOI":"10.4254\/wjh.v11.i4.344","volume":"11","author":"MV Espelt","year":"2019","unstructured":"Espelt MV, Bacigalupo ML, Carabias P, Troncoso MF. MicroRNAs contribute to ATP-binding cassette transporter- and autophagy-mediated chemoresistance in hepatocellular carcinoma. World J Hepatol. 2019;11:344\u201358.","journal-title":"World J Hepatol."},{"key":"4520_CR61","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/sj.bjc.6605895","volume":"103","author":"J Zhang","year":"2010","unstructured":"Zhang J, Yang Y, Yang T, Liu Y, Li A, Fu S, et al. microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer. 2010;103:1215\u201320.","journal-title":"Br J Cancer"},{"key":"4520_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-016-0380-8","volume":"2","author":"LJ Luo","year":"2017","unstructured":"Luo LJ, Zhang LP, Duan CY, Wang B, He NN, Abulimiti P, et al. The inhibition role of miR-22 in hepatocellular carcinoma cell migration and invasion via targeting CD147. Cancer Cell Int. 2017;2:17.","journal-title":"Cancer Cell Int."},{"key":"4520_CR63","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s13046-019-1402-x","volume":"38","author":"Z Leung","year":"2019","unstructured":"Leung Z, Ko FCF, Tey SK, Kwong EML, Mao X, Liu BHM, et al. Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells. J Exp Clin Cancer Res. 2019;38:423. 2019","journal-title":"J Exp Clin Cancer Res."},{"key":"4520_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-5-30","volume":"5","author":"CH Choi","year":"2005","unstructured":"Choi CH. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 2005;5:30.","journal-title":"Cancer Cell Int."},{"key":"4520_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2011.61","volume":"2","author":"M Saxena","year":"2011","unstructured":"Saxena M, Stephens MA, Pathak H, Rangarajan A. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2011;2:e179.","journal-title":"Cell Death Dis."},{"key":"4520_CR66","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1159\/000341860","volume":"58","author":"Y Chen","year":"2012","unstructured":"Chen Y, Li L, Zeng J, Wu K, Zhou J, Guo P, et al. Twist confers chemoresistance to anthracyclines in bladder cancer through upregulating P-glycoprotein. Chemotherapy. 2012;58:264\u201372.","journal-title":"Chemotherapy"},{"key":"4520_CR67","first-page":"415","volume":"41","author":"Z Huang","year":"2019","unstructured":"Huang Z, Liang X, Wu W, Chen X, Zeng Q, Yang M, et al. Mechanisms underlying the increased chemosensitivity of bortezomib-resistant multiple myeloma by silencing nuclear transcription factor Snail1. Oncol Rep. 2019;41:415\u201326.","journal-title":"Oncol Rep."},{"key":"4520_CR68","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1038\/onc.2010.567","volume":"30","author":"M He","year":"2011","unstructured":"He M, Zhao M, Shen B, Prise KM, Shao C. Radiation-induced intercellular signaling mediated by cytochrome-c via a p53-dependent pathway in hepatoma cells. Oncogene. 2011;30:1947\u201355.","journal-title":"Oncogene"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04520-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04520-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04520-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T19:42:34Z","timestamp":1726515754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-04520-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["4520"],"URL":"https:\/\/doi.org\/10.1038\/s41419-022-04520-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"assertion":[{"value":"18 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were performed according to protocols approved by the Instituto de Biolog\u00eda y Medicina Experimental-Instructional Animal Care and Use Committee (IACUC) committee and in agreement with the National Institutes of Health (NIH) Guide for Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"79"}}